Century Therapeutics (IPSC) Stock Price, News & Analysis

Company Overview

Century Therapeutics, Inc., a biotechnology company, engages in the development of genetically engineered allogeneic cell therapies for the treatment of solid tumor and hematological malignancies. Its lead product candidate is CNTY-101, an allogeneic, induced pluripotent stem cells (iPSCs)-derived chimeric antigen receptors (CAR)-iNK cell therapy, under Phase 1 trials targeting CD19 for relapsed, refractory B-cell lymphoma. The company is also involved in the development of CNTY-102, a bi-specific CD19 + CD22 CAR-iT product candidate for relapsed, refractory B-cell lymphoma and other B-cell malignancies; and CNTY-107, a Nectin-4 CAR-iT targeted product candidate for Nectin-4 positive solid tumors. In addition, it has a strategic collaboration with Bristol-Myers Squibb Company to develop and commercialize up to four iNK or iT programs, including CNTY-104, a multi-specific collaboration program targeting acute myeloid leukemia; and CNTY-106, a multi-specific collaboration program for multiple myeloma. The company was incorporated in 2018 and is headquartered in Philadelphia, Pennsylvania.

Key Stats

• Today's Range: $0.51 to $0.56
• 50-Day Range: $0.51 to $0.91
• 52-Week Range: $0.51 to $4.43
• Volume: 297,599 shs
• Average Volume: 384,662 shs
• Market Capitalization: $44.13 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $5.00
• Consensus Rating: Buy

Century Therapeutics Stock Analysis - MarketRank™

Century Therapeutics scored higher than 46% of companies evaluated by MarketBeat, and ranked 634th out of 935 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

Century Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 5 buy ratings, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Century Therapeutics has only been the subject of 4 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Century Therapeutics are expected to decrease in the coming year, from ($1.61) to ($1.79) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Century Therapeutics is -0.28, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Century Therapeutics is -0.28, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Century Therapeutics has a P/B Ratio of 0.17. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

8.70% of the float of Century Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Century Therapeutics has a short interest ratio ("days to cover") of 6.6.

Change versus previous month

Short interest in Century Therapeutics has recently decreased by 0.88%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Century Therapeutics does not currently pay a dividend.

Dividend Growth

Century Therapeutics does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

8.70% of the float of Century Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Century Therapeutics has a short interest ratio ("days to cover") of 6.6.

Change versus previous month

Short interest in Century Therapeutics has recently decreased by 0.88%, indicating that investor sentiment is improving.

News and Social Media

• Score: 2.6 / 5
• News Sentiment: 0.64

News Sentiment

Century Therapeutics has a news sentiment score of 0.64. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.82 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 11 news articles for Century Therapeutics this week, compared to 2 articles on an average week.

Search Interest

3 people have searched for IPSC on MarketBeat in the last 30 days.

MarketBeat Follows

Only 1 people have added Century Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Century Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $4,655.00 in company stock.

Percentage Held by Insiders

Only 6.80% of the stock of Century Therapeutics is held by insiders.

Percentage Held by Institutions

50.20% of the stock of Century Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

IPSC Stock Analysis - Frequently Asked Questions

How have IPSC shares performed this year?

Century Therapeutics' stock was trading at $1.01 at the start of the year. Since then, IPSC stock has decreased by 49.2% and is now trading at $0.5129.
View the best growth stocks for 2025 here.

How were Century Therapeutics' earnings last quarter?

Century Therapeutics, Inc. (NASDAQ:IPSC) issued its earnings results on Wednesday, March, 19th. The company reported ($0.43) EPS for the quarter, beating the consensus estimate of ($0.45) by $0.02. The company earned $4.18 million during the quarter, compared to the consensus estimate of $0.67 million. Century Therapeutics had a negative trailing twelve-month return on equity of 61.66% and a negative net margin of 4,837.73%.

When did Century Therapeutics IPO?

Century Therapeutics (IPSC) raised $201 million in an initial public offering on Friday, June 18th 2021. The company issued 10,600,000 shares at $18.00-$20.00 per share. J.P. Morgan, BofA Securities, SVB Leerink and Piper Sandler acted as the underwriters for the IPO.

Who are Century Therapeutics' major shareholders?

Top institutional investors of Century Therapeutics include Casdin Capital LLC (6.10%), VR Adviser LLC (4.65%), Millennium Management LLC (1.89%) and Renaissance Technologies LLC (1.41%). Insiders that own company stock include Versant Venture Capital Vi, L, Brent Pfeiffenberger, Douglas Carr, Gregory Russotti, Luis Borges and Adrienne Farid.
View institutional ownership trends.

How do I buy shares of Century Therapeutics?

Shares of IPSC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Century Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Century Therapeutics investors own include The RMR Group (RMR), Waste Connections (WCN), American Water Works (AWK), iShares Micro-Cap ETF (IWC), DiamondRock Hospitality (DRH), AUO (AUOTY) and Triple Flag Precious Metals (TFPM).

Company Calendar

• Last Earnings: 3/19/2025
• Today: 3/30/2025
• Next Earnings (Estimated): 5/08/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Biological products, except diagnostic
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:IPSC
• CIK: 1850119
• Web: www.centurytx.com
• Phone: 267-817-5790
• Fax: N/A
• Employees: 170
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $5.00
• High Stock Price Target: $7.00
• Low Stock Price Target: $2.00
• Potential Upside/Downside: +874.8%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 5 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($1.63)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-136,670,000.00
• Net Margins: -4,837.73%
• Pretax Margin: -4,869.53%
• Return on Equity: -61.66%
• Return on Assets: -31.78%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 10.39
• Quick Ratio: 10.39

Sales & Book Value

• Annual Sales: $6.59 million
• Price / Sales: 6.70
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $3.06 per share
• Price / Book: 0.17

Miscellaneous

• Outstanding Shares: 86,045,000
• Free Float: 79,247,000
• Market Cap: $44.13 million
• Optionable: Optionable
• Beta: 1.75